Fresenius completed mAbxience deal. Fresenius stock trades 1.02 percent above Xetra close

Published on 10/13/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 core net income rose 14.00 percent to EUR 470 million. Fresenius stock costs EUR 43.44 on October 13, 2026 versus the EUR 43.00 Xetra close.

Key points in brief

Fresenius completed the acquisition of the remaining 45 percent of mAbxience for up to EUR 750 million on September 30, 2026.
Q2 2026 core net income rose 14.00 percent to EUR 470 million, while revenue increased 6.00 percent to EUR 5.864 billion.
Fresenius stock was trading at EUR 43.44 at Lang & Schwarz on October 13, 2026, 1.02 percent above the EUR 43.00 Xetra close.
Jefferies maintained a Buy rating and a EUR 55.00 price target on October 2, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) was trading at EUR 43.44 at Lang & Schwarz on October 13, 2026 at 9:48 a.m. CEST, up 1.02 percent versus the Xetra close of October 12, 2026 at EUR 43.00. The company completed the acquisition of the remaining 45 percent of mAbxience on September 30, 2026, a transaction announced by EQS News on October 1, 2026.

Three milestones shape the story

On July 31, 2026, Fresenius established a healthcare venture fund of more than EUR 200 million, according to Fresenius. On August 5, 2026, Q2 revenue reached EUR 5.864 billion, up 6.00 percent year over year, while core net income rose 14.00 percent to EUR 470 million, per the company's investor-relations information. The September 30, 2026 mAbxience transaction then added up to EUR 750 million of consideration and gave Fresenius full ownership of the biosimilars platform, as EQS News reported.

What does full ownership change?

The deal gives Fresenius control of the platform's future investment, manufacturing and licensing decisions. It includes a contingent payment of EUR 50 million and is expected to contribute immediately to group core earnings per share, according to EQS News. The release also states that no change was made to full-year 2026 guidance.

For the second quarter of 2026, group EBIT rose 10.00 percent to EUR 719 million, while core earnings per share increased 14.00 percent to EUR 0.83. The combination of double-digit earnings growth and full ownership of mAbxience makes execution in Kabi's biopharma business a measurable part of the investment case.

Jefferies keeps a EUR 55.00 target

Jefferies maintained its Buy rating and EUR 55.00 price target in a research note dated October 2, 2026, according to FinanzNachrichten. The target lies 26.61 percent above the Lang & Schwarz price of EUR 43.44, putting the analyst view well above the current market level.

Next results arrive November 4

Fresenius lists November 4, 2026 as the next event for publication of its third-quarter financial report, according to Fresenius. That report will provide the next quantified test of the earnings improvement shown in the second quarter.

Fresenius stock holds above EUR 43.00

At EUR 43.44, Fresenius stock stood 1.02 percent above the Xetra close of October 12, 2026 at EUR 43.00. The current quote was an in-trading indication at Lang & Schwarz on October 13, 2026 at 9:48 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.